Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for oncogene v- fms
Most Correlated Studies
- L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
- L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
- L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
- L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
- L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
Most Relevant Literature
- Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in b…
- Regulation of closely juxtaposed proto-oncogene c-fms and HMGXB3 gene expression by mRNA 3' end poly…
- M2 differentiation of MonoMac-1 cell line induced by M-CSF and glucocorticoid pathways.
- Inhibition of IL-34 Unveils Tissue-Selectivity and Is Sufficient to Reduce Microglial Proliferation …
- Deletion of a Csf1r enhancer selectively impacts CSF1R expression and development of tissue macropha…
Most Relevant Clinical Trials
- Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
- Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
- Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acut…
- A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) I…
- Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
